3 active not recruiting, 3 completed, 3 recruiting, 2 terminated. 8 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 3, Active not recruiting 2, Terminated 2, Recruiting 1 |
| Phase 1 | 5 | Recruiting 3, Active not recruiting 1, Completed 1 |
Follow Refractory Melanoma: new trials by email Literature Review of Refractory Melanoma trials Research Report on Refractory Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma DOC1021, Tumor resection, pIFN (peginterferon alfa-2a) - Refractory Melanoma | Phase 1 / Phase 2 | Recruiting | Diakonos Oncology Corporation | 35 | 2026-04-06 | 2026-09-09 |
| Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel) Cyclophosphamide, Fludarabine - Phase 1, Recurrent Melanoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 39 | 2025-02-25 | 2026-10-05 |
| Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma Alpha-type-1 Polarized Dendritic Cells, Celecoxib, PD-1 Ligand Inhibitor - HLA-A2 Positive Cells Present, Refractory Melanoma | Phase 2 | Terminated | Roswell Park Cancer Institute | 1 | 2024-11-13 | 2026-02-25 |
| Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors Rigosertib, Pembrolizumab, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Terminated | Vanderbilt-Ingram Cancer Center | 7 | 2023-05-09 | 2026-09-16 |
| Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC) Pixatimod, Nivolumab, Cyclophosphamide (low dose) - NSCLC, Metastatic Colorectal Carcinoma | Phase 2 | Completed | Diwakar Davar | 13 | 2021-12-09 | 2026-09-08 |
| IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors Bevacizumab, Glutaminase-1 Inhibitor IACS-6274, Paclitaxel - Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 54 | 2021-09-30 | 2026-10-06 |
| Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial Tipifarnib - Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 5 | 2020-10-13 | 2026-10-16 |
| Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases Atezolizumab, Bevacizumab, Cobimetinib - BRAF V600 Wild Type, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 29 | 2017-06-15 | 2026-06-25 |
| Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Colorectal Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 59 | 2015-04-08 | 2026-10-07 |
| Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 140 | 2015-03-30 | 2023-10-17 |
| Study of CP-675,206 in Refractory Melanoma CP-675,206 - Refractory Melanoma | Phase 2 | Completed | AstraZeneca | 251 | 2005-12-01 | 2012-06-07 |
| Compassionate Use of Vidutolimod Vidutolimod - Refractory Melanoma | No longer available | Regeneron Pharmaceuticals | 2026-01-08 |
Melanoma (12) · Colorectal Neoplasms (2) · Lymphoma, Non-Hodgkin (2) · Neuroblastoma (2) · Neuroectodermal Tumors, Primitive, Peripheral (2) · Osteosarcoma (2) · Ovarian Neoplasms (2) · Rhabdomyosarcoma (2) · Sarcoma (2) · Brain Neoplasms (1) · Carcinoma, Renal Cell (1) · Chondrosarcoma (1) · Endometrial Neoplasms (1) · Ependymoma (1) · Glioma (1)
Neoplasms (12) · Neoplasms by Histologic Type (12) · Neoplasms by Site (12) · Neoplasms, Germ Cell and Embryonal (12) · Neoplasms, Nerve Tissue (12) · Neuroectodermal Tumors (12) · Neuroendocrine Tumors (12) · Nevi and Melanomas (12) · Skin Diseases (12) · Skin Neoplasms (12) · Skin and Connective Tissue Diseases (12) · Neoplasms, Connective and Soft Tissue (4) · Neoplasms, Glandular and Epithelial (4) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3)
Bevacizumab (2) · Biopsy (2) · Cyclophosphamide (2) · Disulfides (2) · Immunoglobulin G (2) · Nivolumab (2) · pembrolizumab (2) · CTLA-4 Antigen (1) · Celecoxib (1) · Immune Checkpoint Inhibitors (1) · Interferon alpha-2 (1) · Introns (1) · Ipilimumab (1) · Magnetic Resonance Spectroscopy (1) · ON 01910 (1)
M.D. Anderson Cancer Center (3) · National Cancer Institute (NCI) (3) · AstraZeneca (1) · Diakonos Oncology Corporation (1) · Diwakar Davar (1) · Regeneron Pharmaceuticals (1) · Roswell Park Cancer Institute (1) · Vanderbilt-Ingram Cancer Center (1)
United States (11) · Canada (3) · Argentina (1) · Australia (1) · France (1) · Germany (1) · Italy (1) · Puerto Rico (1) · Spain (1) · United Kingdom (1)
Christine A Pratilas (1) · Crystal L Mackall (1) · Diwakar Davar, MD (1) · Douglas Johnson, MD (1) · Frank S Hodi (1) · Hussein A Tawbi (1) · Igor Puzanov (1) · Isabella C Glitza Oliva, MD (1) · Timothy A Yap, MD (1)
PMID 31401903, PMID 32192573, PMID 35264434, PMID 36634920, PMID 38236249, PMID 42853672
P01CA234212 (1), U01CA062490 (1), U10CA180886 (1), UM1CA097452 (1), UM1CA186644 (1), UM1CA186709 (1)